DB:2CH

Stock Analysis Report

China Biologic Products Holdings

Executive Summary

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People’s Republic of China.


Snowflake Analysis

Flawless balance sheet and good value.


Similar Companies

Share Price & News

How has China Biologic Products Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2CH has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.0%

2CH

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

26.5%

2CH

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: 2CH exceeded the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: 2CH exceeded the German Market which returned -17.5% over the past year.


Shareholder returns

2CHIndustryMarket
7 Day-2.0%11.2%7.3%
30 Day-3.9%-5.3%-17.9%
90 Day-3.9%-21.9%-25.8%
1 Year26.5%26.5%-4.9%-5.1%-15.1%-17.7%
3 Yearn/a17.7%16.5%-18.7%-25.6%
5 Yearn/a-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is China Biologic Products Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is China Biologic Products Holdings undervalued compared to its fair value and its price relative to the market?

40.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 2CH (€99) is trading below our estimate of fair value (€166.23)

Significantly Below Fair Value: 2CH is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 2CH is good value based on its PE Ratio (30.6x) compared to the Biotechs industry average (34x).

PE vs Market: 2CH is poor value based on its PE Ratio (30.6x) compared to the German market (16.5x).


Price to Earnings Growth Ratio

PEG Ratio: 2CH is poor value based on its PEG Ratio (2.7x)


Price to Book Ratio

PB vs Industry: 2CH is good value based on its PB Ratio (2.5x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is China Biologic Products Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

11.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2CH's forecast earnings growth (11.5% per year) is above the savings rate (-0.4%).

Earnings vs Market: 2CH's earnings (11.5% per year) are forecast to grow slower than the German market (14.2% per year).

High Growth Earnings: 2CH's earnings are forecast to grow, but not significantly.

Revenue vs Market: 2CH's revenue (11.4% per year) is forecast to grow faster than the German market (4.2% per year).

High Growth Revenue: 2CH's revenue (11.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2CH's Return on Equity is forecast to be low in 3 years time (9.4%).


Next Steps

Past Performance

How has China Biologic Products Holdings performed over the past 5 years?

11.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2CH has high quality earnings.

Growing Profit Margin: 2CH's current net profit margins (27.2%) are higher than last year (26.8%).


Past Earnings Growth Analysis

Earnings Trend: 2CH's earnings have grown by 11.1% per year over the past 5 years.

Accelerating Growth: 2CH's earnings growth over the past year (9.7%) is below its 5-year average (11.1% per year).

Earnings vs Industry: 2CH earnings growth over the past year (9.7%) exceeded the Biotechs industry 8.7%.


Return on Equity

High ROE: 2CH's Return on Equity (9.2%) is considered low.


Next Steps

Financial Health

How is China Biologic Products Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 2CH's short term assets ($1.3B) exceed its short term liabilities ($119.3M).

Long Term Liabilities: 2CH's short term assets ($1.3B) exceed its long term liabilities ($43.7M).


Debt to Equity History and Analysis

Debt Level: 2CH is debt free.

Reducing Debt: 2CH has no debt compared to 5 years ago when its debt to equity ratio was 36.2%.

Debt Coverage: 2CH has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 2CH has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: 2CH has a high level of physical assets or inventory.

Debt Coverage by Assets: 2CH's debt is covered by short term assets (assets are 1.4633607045292E+18x debt).


Next Steps

Dividend

What is China Biologic Products Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2CH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2CH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2CH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2CH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2CH's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average board tenure


CEO

Joseph Chow (57yo)

0.83

Tenure

Mr. Joseph Chow serves as Senior Advisor at U.S.-China Green Investment Management Ltd. He served as Managing Director of Centurium Capital. Mr. Chow served as the Managing Director of Moelis & Company fro ...


Board Members

NamePositionTenureCompensationOwnership
Joseph Chow
Chairman & CEO0.83yrno data0.038% $1.4m
Yungang Lu
Independent Director8yrsno data0.14% $5.4m
Hui Li
Director6.33yrsno data0.073% $2.8m
Sean S. Shao
Independent Director11.67yrsno data0.040% $1.5m
Qi Ning
Independent Director1.67yrsno datano data
Yue'e Zhang
Director2.17yrsno data0.0052% $196.2k

4.3yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 2CH's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.


Top Shareholders

Company Information

China Biologic Products Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: China Biologic Products Holdings, Inc.
  • Ticker: 2CH
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.183b
  • Listing Market Cap: US$3.773b
  • Shares outstanding: 38.48m
  • Website: https://www.chinabiologic.com

Number of Employees


Location

  • China Biologic Products Holdings, Inc.
  • Jialong International Tower
  • 18th floor
  • Beijing
  • 100125
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CBPO NBMV (Bolsa Mexicana de Valores)YesNew Common StockMXMXNJul 2017
CBPONasdaqGS (Nasdaq Global Select)YesNew Common StockUSUSDJul 2017
2CHDB (Deutsche Boerse AG)YesNew Common StockDEEURJul 2017
0YWSLSE (London Stock Exchange)YesNew Common StockGBUSDJul 2017

Biography

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People’s Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People’s Republic of China. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 23:42
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.